For more than 25 years, Dr. Kathleen Anne Welsh-Bohmer’s research activities have been focused around developing effective prevention and treatment strategies to eliminate the onset of cognitive disorders occurring in later life. As one of the true leaders in Alzheimer’s Disease scientific research, Dr. Welsh-Bohmer brings vast expertise to VeraSci. As Vice President for Neurodegenerative Disorders at VeraSci, she leads a team of scientists and operational experts in developing new tools for assessing cognitive and clinical changes and supporting clinical trials in MCI, Alzheimer’s disease and other neurological and age-related disorders.
Most recently, Dr. Welsh-Bohmer provided oversight of the neuropsychology scientific operations of a Phase III global clinical trial to delay the onset of Alzheimer’s disease entitled the “TOMMORROW” study. The methods her team developed for this study filled an information void and had implications for accelerating global clinical trials in Alzheimer’s disease prevention.
Dr. Welsh-Bohmer’s work as Director of the Joseph and Kathleen Bryan Alzheimer’s Disease Research Center (Bryan ADRC) at Duke University Medical Center was centered around discovering the biological basis of Alzheimer’s disease and developing methods to enhance early diagnosis and speed drug discovery. In addition to her current work at VeraSci, she serves as the Director of Alzheimer’s Disease Clinical Trials within the Duke Clinical Research Institute and is a Professor of Psychiatry with a secondary appointment in the Department of Neurology at Duke University.
Therapeutic Focus: Preclinical Alzheimer’s Disease, Mild Cognitive Impairment, Alzheimer’s Disease Dementia, Cognitive Aging, Vascular Cognitive Impairment, Lewy Body Dementia, Frontotemporal Dementia